Antidepressants have similar efficacy but differing side effects, according to new findings released by AHRQ. Authors of a comparative review analyzed the risks and benefits of a dozen second-generation antidepressants by examining 293 published studies and found that, overall, they led to similar rates of improvement: 54% had partial improvement, and 38% saw no improvement. On average, 61% of patients experienced at least one side effect. Venlafaxine showed a higher incidence of nausea and vomiting than the SSRIs, sertraline was more likely to cause diarrhea than some others, mirtazapine led to higher weight gain, and trazodone caused more sleepiness. Paroxetine and venlafaxine had the highest rates of discontinuation syndrome, and fluoxetine had the lowest. Bupropion was less likely to cause sexual dysfunction than some others and paroxetine was associated with higher rates.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.